Quality of life assessment is becoming increasingly important in oncology: a paper published in The Lancet Oncology by Andrew Bottomley of the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, and [more]
The European Oncology Nursing Society has compiled the evidence to show the value of the work cancer nurses do, and the specialist training and education they need to do it. Now they’re calling on policy [more]
It’s not just a matter of clinical outcomes: quality of life goes far beyond the final result of a cancer treatment and involves several aspects of daily life, both for patients and their caregivers. And [more]
My good friend Professor Richard Sullivan wrote an excellent piece for Cancer World on how to reverse the decline in the benefit per cost of cancer interventions. It gave me food for thought. Sullivan gave [more]
Despite growing precision in understanding the biology of breast cancer, progress in extending survival of people with metastatic disease remains frustratingly slow. Median survival is only about three years, having edged up only slightly in [more]
A growing body of literature has described the so called “financial toxicity” of cancer, a common consequence of treatments, that sometimes leads patients to bankruptcy, and affects quality of life and clinical outcomes. “We don’t [more]
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]
Day two of ABC-Lisbon featured a pioneer in metastatic breast cancer advocacy, Musa Mayer, who gave the ABC Award lecture. Mayer told the history of how the “silent voices” of women with advanced disease came [more]